Oncotarget: Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2)

(Impact Journals LLC) The cover for issue 29 of Oncotarget features Figure 5, " In vivo effects of treatment with L-Grb2 in combination with anti-angiogenic therapy in an ovarian tumor model, " by Lara, et al. which reported that adaptor proteins such as growth factor receptor-bound protein-2 play important roles in cancer cell signaling. In the present study, the authors examined the biological effects of liposomal antisense oligodeoxynucleotide that blocks Grb2 expression in gynecologic cancer models.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news